Related Experiment Videos
High-dose intravenous dalteparin can be monitored effectively using standard coagulation times
James M Wilson1, Jerry Gilbert, Mary Harlan
1Department of Cardiology, St. Luke's Episcopal Hospital/Texas Heart Institute, Baylor College of Medicine, University of Houston School of Pharmacy, Houston, Texas 77030, USA. jwilson@sleh.com
Summary
Standard coagulation tests accurately estimate dalteparin drug concentration for guiding dosing, particularly during high-dose therapy. Further trials are needed to link monitoring to clinical efficacy and risk-benefit.
Area of Science:
- Pharmacology
- Clinical Coagulation
Background:
- Low-molecular-weight heparins (LMWHs) require safe and effective dosing algorithms, especially for percutaneous coronary interventions.
- Understanding dalteparin pharmacokinetics and monitoring utility is crucial for optimizing treatment.
Purpose of the Study:
- To investigate the pharmacokinetics of intravenous dalteparin.
- To evaluate the accuracy of standard coagulation monitoring techniques for estimating dalteparin concentration and guiding dosage.
Main Methods:
- Twenty healthy volunteers received three intravenous dalteparin doses at 2-week intervals.
- Measurements included anti-IIa, anti-Xa, activated partial thromboplastin time (aPTT), activated clotting time (ACT), and low-range ACT (LR-ACT) over 8 hours.
Main Results:
- Intravenous dalteparin exhibited a half-life of 77 minutes, with minor dose-related variations.
- aPTT and ACT measurements showed a strong correlation with anti-Xa activity, indicating sensitivity to dalteparin's anticoagulant effects.
- Coagulation time monitoring demonstrated agreement comparable to unfractionated heparin monitoring, suggesting utility for dose estimation.
Conclusions:
- Standard coagulation times are sensitive to dalteparin's effects and can estimate drug concentration, especially in high-dose scenarios.
- Further clinical trials are essential to establish the relationship between monitoring, clinical efficacy, and risk-benefit profiles of dalteparin therapy.